penicillamine has been researched along with Alzheimer Disease in 11 studies
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.
penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
Excerpt | Relevance | Reference |
---|---|---|
"When compared to patients prescribed donepezil, galantamine, or memantine, individuals prescribed rivastigmine were almost twice as likely to report dysphagia as an adverse event." | 8.12 | Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. ( Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022) |
"When compared to patients prescribed donepezil, galantamine, or memantine, individuals prescribed rivastigmine were almost twice as likely to report dysphagia as an adverse event." | 4.12 | Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. ( Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022) |
"Some of the implications are that Alzheimer's disease and other diseases of neurodegeneration and fibrotic, inflammatory, and autoimmune diseases may be treatable by lowering the availability of free copper." | 2.44 | The risks of free copper in the body and the development of useful anticopper drugs. ( Brewer, GJ, 2008) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (9.09) | 18.2507 |
2000's | 7 (63.64) | 29.6817 |
2010's | 1 (9.09) | 24.3611 |
2020's | 2 (18.18) | 2.80 |
Authors | Studies |
---|---|
Moret, V | 1 |
Laras, Y | 1 |
Pietrancosta, N | 1 |
Garino, C | 1 |
Quéléver, G | 1 |
Rolland, A | 1 |
Mallet, B | 1 |
Norreel, JC | 1 |
Kraus, JL | 1 |
Bu, K | 1 |
Patel, D | 1 |
Morris, R | 1 |
Han, W | 1 |
Umeukeje, G | 1 |
Zhu, T | 1 |
Cheng, F | 1 |
Cilliers, K | 1 |
Sun, D | 1 |
Zhang, W | 1 |
Yu, Q | 1 |
Chen, X | 1 |
Xu, M | 1 |
Zhou, Y | 1 |
Liu, J | 1 |
Brewer, GJ | 1 |
Rossi, L | 2 |
Squitti, R | 2 |
Pasqualetti, P | 2 |
Marchese, E | 1 |
Cassetta, E | 2 |
Forastiere, E | 1 |
Rotilio, G | 1 |
Rossini, PM | 2 |
Finazzi-Agró, A | 2 |
Cui, Z | 1 |
Lockman, PR | 1 |
Atwood, CS | 1 |
Hsu, CH | 1 |
Gupte, A | 1 |
Allen, DD | 1 |
Mumper, RJ | 1 |
Gasparini, L | 1 |
Ghidoni, R | 1 |
Alberici, AC | 1 |
Benussi, L | 1 |
Moratto, D | 1 |
Trabucchi, M | 1 |
Growdon, JH | 1 |
Nitsch, RM | 1 |
Binetti, G | 1 |
Fass, U | 1 |
Panickar, K | 1 |
Personett, D | 1 |
Bryan, D | 1 |
Williams, K | 1 |
Gonzales, J | 1 |
Sugaya, K | 1 |
McKinney, M | 1 |
Cherny, RA | 1 |
Barnham, KJ | 1 |
Lynch, T | 1 |
Volitakis, I | 1 |
Li, QX | 1 |
McLean, CA | 1 |
Multhaup, G | 1 |
Beyreuther, K | 1 |
Tanzi, RE | 1 |
Masters, CL | 1 |
Bush, AI | 1 |
Moffa, F | 1 |
Cortesi, M | 1 |
Colloca, A | 1 |
2 reviews available for penicillamine and Alzheimer Disease
Article | Year |
---|---|
Trace element alterations in Alzheimer's disease: A review.
Topics: Alzheimer Disease; Clioquinol; Copper; Deferoxamine; Humans; Metals; Penicillamine; Siderophores; Tr | 2021 |
The risks of free copper in the body and the development of useful anticopper drugs.
Topics: Alzheimer Disease; Angiogenesis Inhibitors; Autoimmunity; Copper; Fibrosis; Hepatolenticular Degener | 2008 |
2 trials available for penicillamine and Alzheimer Disease
Article | Year |
---|---|
Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Chi-Square Distribution; Copper; D | 2002 |
d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chelating Agents; Copper; Disease Progression; Female; H | 2002 |
7 other studies available for penicillamine and Alzheimer Disease
Article | Year |
---|---|
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
Topics: Alzheimer Disease; Animals; Chelating Agents; Clioquinol; Copper; Heterocyclic Compounds, 1-Ring; Mo | 2006 |
Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Clozapine | 2022 |
Chiral penicillamine-modified selenium nanoparticles enantioselectively inhibit metal-induced amyloid β aggregation for treating Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cell Survival; Me | 2017 |
Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases.
Topics: Alzheimer Disease; Central Nervous System Diseases; Chelating Agents; Copper; Drug Carriers; Drug St | 2005 |
Modulation of presenilin-1 processing by nitric oxide during apoptosis induced by serum withdrawal and glucose deprivation.
Topics: Alzheimer Disease; Apoptosis; Benzoates; Culture Media, Serum-Free; Cytochrome c Group; Deoxyglucose | 1999 |
Differential vulnerability of primary cultured cholinergic neurons to nitric oxide excess.
Topics: Acetylcholine; Alzheimer Disease; Animals; Brain Stem; Cell Survival; Cells, Cultured; Choline O-Ace | 2000 |
Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Chelating Agents; Copper; Humans; Mice; Mi | 2000 |